Endologix receives FDA approval for smaller-size stent grafts

By Elaine Rigoli

Tampa, Fla., April 25 - Endologix, Inc. has received approval from the Food and Drug Administration to market new short-body/short-limb variants of the Powerlink system endoluminal stent graft (ELG) for the minimally invasive treatment of abdominal aortic aneurysms.

The company expects that the two Powerlink-120 models will address 5% to 10% of abdominal aortic aneurysm patients currently excluded from treatment due to anatomical considerations.

Endologix plans to begin marketing the new devices in May.

"We envision our Powerlink System as a platform, and our new short-body/short-limb ELG configurations are among several product enhancements and line extensions that we plan to introduce in an effort to expand the Powerlink system's commercial use," president and chief executive officer Paul McCormick said in a news release.

Based in Irvine, Calif., Endologix develops and manufactures minimally invasive treatments for vascular diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.